OBJECTIVE: To determine whether 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) brain regional values in individuals without dementia predict and correlate with future cognitive change. DESIGN: Two-year, longitudinal follow-up study. SETTING: A university research institute. PARTICIPANTS: Volunteer sample of 43 middle-aged and older persons (median age, 64 years), including 21 with mild cognitive impairment (MCI) and 22 with normal aging. MAIN OUTCOME MEASURES: Longitudinal [(18)F]FDDNP positron emission tomography (PET) binding values in the medial and lateral temporal, posterior cingulate, parietal, frontal, and global (mean) regions of interest; neuropsychological test battery measuring 5 cognitive domains, including memory, language, attention (and information-processing speed), executive functioning, and visuospatial ability. RESULTS: For the entire study group (MCI and normal aging), increases in frontal, posterior cingulate, and global binding at follow-up correlated with progression of memory decline (r = -0.32 to -0.37, P = .03 to .01) after 2 years. Moreover, higher baseline [(18)F]FDDNP binding was associated with future decline in most cognitive domains, including language, attention, executive, and visuospatial abilities (r = -0.31 to -0.56, P = .05 to .002). For the MCI group, frontal and parietal [(18)F]FDDNP binding yielded the greatest diagnostic accuracy in identifying converters to Alzheimer disease vs nonconverters after 2 years, with an area under the receiver operating characteristic curve of 0.88 (95% CI, 0.72-1.00) compared with 0.68 (95% CI, 0.45-0.91) for medial temporal binding. CONCLUSIONS: [(18)F]FDDNP PET regional binding patterns are consistent with known neuropathologic patterns of plaque and tangle brain accumulation, spreading from the medial temporal to other neocortical regions as disease progresses. Because binding patterns predict future cognitive decline and increase over time along with clinical decline, [(18)F]FDDNP PET scanning may have practical utility in identifying people at risk for future cognitive decline and in tracking the effectiveness of novel interventions designed to prevent or delay neurodegeneration and cognitive decline.
OBJECTIVE: To determine whether 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) brain regional values in individuals without dementia predict and correlate with future cognitive change. DESIGN: Two-year, longitudinal follow-up study. SETTING: A university research institute. PARTICIPANTS: Volunteer sample of 43 middle-aged and older persons (median age, 64 years), including 21 with mild cognitive impairment (MCI) and 22 with normal aging. MAIN OUTCOME MEASURES: Longitudinal [(18)F]FDDNP positron emission tomography (PET) binding values in the medial and lateral temporal, posterior cingulate, parietal, frontal, and global (mean) regions of interest; neuropsychological test battery measuring 5 cognitive domains, including memory, language, attention (and information-processing speed), executive functioning, and visuospatial ability. RESULTS: For the entire study group (MCI and normal aging), increases in frontal, posterior cingulate, and global binding at follow-up correlated with progression of memory decline (r = -0.32 to -0.37, P = .03 to .01) after 2 years. Moreover, higher baseline [(18)F]FDDNP binding was associated with future decline in most cognitive domains, including language, attention, executive, and visuospatial abilities (r = -0.31 to -0.56, P = .05 to .002). For the MCI group, frontal and parietal [(18)F]FDDNP binding yielded the greatest diagnostic accuracy in identifying converters to Alzheimer disease vs nonconverters after 2 years, with an area under the receiver operating characteristic curve of 0.88 (95% CI, 0.72-1.00) compared with 0.68 (95% CI, 0.45-0.91) for medial temporal binding. CONCLUSIONS: [(18)F]FDDNP PET regional binding patterns are consistent with known neuropathologic patterns of plaque and tangle brain accumulation, spreading from the medial temporal to other neocortical regions as disease progresses. Because binding patterns predict future cognitive decline and increase over time along with clinical decline, [(18)F]FDDNP PET scanning may have practical utility in identifying people at risk for future cognitive decline and in tracking the effectiveness of novel interventions designed to prevent or delay neurodegeneration and cognitive decline.
Authors: Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio Journal: N Engl J Med Date: 2006-12-21 Impact factor: 91.245
Authors: Jie Liu; Vladimir Kepe; Alenka Zabjek; Andrej Petric; Henry C Padgett; Nagichettiar Satyamurthy; Jorge R Barrio Journal: Mol Imaging Biol Date: 2007 Jan-Feb Impact factor: 3.488
Authors: Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio Journal: Am J Geriatr Psychiatry Date: 2002 Jan-Feb Impact factor: 4.105
Authors: N Tolboom; W M van der Flier; M Yaqub; T Koene; R Boellaard; A D Windhorst; P Scheltens; A A Lammertsma; B N M van Berckel Journal: Neurology Date: 2009-12-15 Impact factor: 9.910
Authors: Gary W Small; Susan Y Bookheimer; Paul M Thompson; Greg M Cole; S-C Huang; Vladimir Kepe; Jorge R Barrio Journal: Lancet Neurol Date: 2008-02 Impact factor: 44.182
Authors: Oscar L Lopez; William J Jagust; Steven T DeKosky; James T Becker; Annette Fitzpatrick; Corinne Dulberg; John Breitner; Constantine Lyketsos; Beverly Jones; Claudia Kawas; Michelle Carlson; Lewis H Kuller Journal: Arch Neurol Date: 2003-10
Authors: Nelleke Tolboom; Wiesje M van der Flier; Maqsood Yaqub; Ronald Boellaard; Nicolaas A Verwey; Marinus A Blankenstein; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel Journal: J Nucl Med Date: 2009-08-18 Impact factor: 10.057
Authors: Gary W Small; Prabha Siddarth; Alison C Burggren; Vladimir Kepe; Linda M Ercoli; Karen J Miller; Helen Lavretsky; Paul M Thompson; Greg M Cole; S C Huang; Michael E Phelps; Susan Y Bookheimer; Jorge R Barrio Journal: Arch Gen Psychiatry Date: 2009-01
Authors: Correne A DeCarlo; Holly A Tuokko; Dorothy Williams; Roger A Dixon; Stuart W S MacDonald Journal: Ageing Res Rev Date: 2014-09-30 Impact factor: 10.895
Authors: Stephen W Scheff; Douglas A Price; Mubeen A Ansari; Kelly N Roberts; Frederick A Schmitt; Milos D Ikonomovic; Elliott J Mufson Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: David A Merrill; Prabha Siddarth; Vladimir Kepe; Pushpa V Raja; Nathan Saito; Linda M Ercoli; Karen J Miller; Helen Lavretsky; Susan Y Bookheimer; Jorge R Barrio; Gary W Small Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Beatrix Krause-Sorio; Prabha Siddarth; Kelsey T Laird; Linda Ercoli; Katherine Narr; Jorge R Barrio; Gary Small; Helen Lavretsky Journal: Int Psychogeriatr Date: 2020-01-23 Impact factor: 3.878
Authors: David A Merrill; Prabha Siddarth; Cyrus A Raji; Natacha D Emerson; Florangel Rueda; Linda M Ercoli; Karen J Miller; Helen Lavretsky; Laurel M Harris; Alison C Burggren; Susan Y Bookheimer; Jorge R Barrio; Gary W Small Journal: Am J Geriatr Psychiatry Date: 2016-05-13 Impact factor: 4.105